- Home
- RMBI vs SPRO Comparison
RMBI vs SPRO Comparison
Compare RMBI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- SPRO
- Stock Information
- Founded
- RMBI 1887
- SPRO 2013
- Country
- RMBI United States
- SPRO United States
- Employees
- RMBI N/A
- SPRO N/A
- Industry
- RMBI Major Banks
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- SPRO Health Care
- Exchange
- RMBI Nasdaq
- SPRO Nasdaq
- Market Cap
- RMBI 140.3M
- SPRO 128.9M
- IPO Year
- RMBI 2019
- SPRO 2017
- Fundamental
- Price
- RMBI $13.37
- SPRO $2.22
- Analyst Decision
- RMBI
- SPRO Buy
- Analyst Count
- RMBI 0
- SPRO 4
- Target Price
- RMBI N/A
- SPRO $5.00
- AVG Volume (30 Days)
- RMBI 13.2K
- SPRO 1.1M
- Earning Date
- RMBI 10-23-2025
- SPRO 11-13-2025
- Dividend Yield
- RMBI 4.48%
- SPRO N/A
- EPS Growth
- RMBI 21.88
- SPRO N/A
- EPS
- RMBI 1.06
- SPRO N/A
- Revenue
- RMBI $44,971,048.00
- SPRO $48,576,000.00
- Revenue This Year
- RMBI N/A
- SPRO N/A
- Revenue Next Year
- RMBI N/A
- SPRO N/A
- P/E Ratio
- RMBI $12.63
- SPRO N/A
- Revenue Growth
- RMBI 6.42
- SPRO N/A
- 52 Week Low
- RMBI $11.37
- SPRO $0.51
- 52 Week High
- RMBI $15.24
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- RMBI 40.79
- SPRO 52.37
- Support Level
- RMBI $13.21
- SPRO $2.16
- Resistance Level
- RMBI $14.14
- SPRO $2.50
- Average True Range (ATR)
- RMBI 0.55
- SPRO 0.12
- MACD
- RMBI -0.04
- SPRO -0.01
- Stochastic Oscillator
- RMBI 25.51
- SPRO 20.00
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.